Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Income from Continuing Operations (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Income from Continuing Operations for 16 consecutive years, with 7629000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 141.5% to 7629000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 13061000.0, a 120.78% increase, with the full-year FY2024 number at 9841000.0, up 111.51% from a year prior.
  • Income from Continuing Operations was 7629000.0 for Q3 2025 at Gyre Therapeutics, up from 2238000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 51632000.0 in Q2 2022 to a low of 81692000.0 in Q4 2023.
  • A 5-year average of 7267210.53 and a median of 1780000.0 in 2023 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: crashed 453.2% in 2021, then skyrocketed 801.18% in 2024.
  • Gyre Therapeutics' Income from Continuing Operations stood at 20387000.0 in 2021, then crashed by 41.21% to 28788000.0 in 2022, then crashed by 183.77% to 81692000.0 in 2023, then skyrocketed by 99.34% to 540000.0 in 2024, then skyrocketed by 1512.78% to 7629000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Income from Continuing Operations are 7629000.0 (Q3 2025), 2238000.0 (Q2 2025), and 3734000.0 (Q1 2025).